Canaccord Genuity started coverage on shares of Stoke Therapeutics (NASDAQ:STOK) in a research report released on Monday, BenzingaRatingsTable reports. The firm issued a buy rating and a $44.00 target price on the stock.
STOK has been the topic of a number of other research reports. JPMorgan Chase & Co. restated a sell rating and issued a $18.00 target price on shares of ABB in a research note on Monday. Cowen restated a buy rating on shares of Avrobio in a research note on Monday.
Shares of Stoke Therapeutics stock opened at $23.89 on Monday. Stoke Therapeutics has a 1 year low of $22.84 and a 1 year high of $31.76.
About Stoke Therapeutics
Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops antisense oligonucleotide medicines to treat the underlying causes of severe genetic diseases. Its lead product candidate, STK-001, to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics, Inc has a partnership with Invitae Corporation to offer epilepsy panel testing.
Recommended Story: How do candlesticks reflect price movement?
Receive News & Ratings for Stoke Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stoke Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.